- Supported exchanges /
- KQ /
- 314130.KQ
Genome & Company (314130 KQ) stock market data APIs
Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The company also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases; and GENA-104 for the treatment of solid tumors, as well as microbiome-based products, including therapeutics, cosmeceuticals, and dietary supplements. In addition, it has a partnership with US Scioto Biosciences for the development of SB-121, which targets disorders related to the gut-brain axis, such as Autism Spectrum Disorder (ASD), as well as disorders related to gut-injury, including Necrotizing Enterocolitis (NEC). The company was founded in 2015 and is based in Seongnam-si, South Korea.
Genome & Company Financial Data Overview
| 2855 | |
| 2790 | |
| - | |
| 2870 | |
| 2780 | |
| 2705-7335 | |
| 0 | |
| 0 | |
| 0 | |
| -29.3955 | |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Genome & Company Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA 0
- Earnings Per Share
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Genome & Company Earnings via APIs
- Latest Release 2024-06-30
- EPS/Forecast NaN
Get Genome & Company End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
